Since HER2 overexpression is both a negative prognostic factor and a predictive factor of the response to anti-HER treatments, we further introduced the comparative analysis between the two groups of patients (with/without obesity), depending on the positive HER2 cases. The gene discussed is ERBB2; the disease is obesity due to melanocortin 4 receptor deficiency.